secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K/A
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001213900-24-095507
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma enters consulting agreement with chairperson's company Cofame
--------------------------------------------------------------------------------

- Estrella Immunopharma entered a Consulting Agreement with Cofame Investment Management, owned by Chairperson Hong Zhang, for advisory services up to three days per week.
- Cofame receives $55,000 upfront and an annual fee of $220,000; Hong Zhang granted option to purchase 1,000,000 shares under the 2023 Omnibus Incentive Plan.
- Option vests 25% on August 1, 2025, with the remaining 75% vesting monthly over 36 months, contingent on continued service.
- The Audit Committee reviewed and approved the agreement as a related-party transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024095507/0001213900-24-095507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024095507/ea022043401-8ka_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-095507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer